Gemcitabine,Vincristine and Cisplatin as Second Line Combination Therapy in Patients With Sarcoma

Inclusion Criteria:

* Give written informed consent prior to study, with understanding that the patient has the right to withdraw from the study at any time without prejudice
* Be female of male and ≥18 and ≤75 years of age
* Be ambulatory and have ECOG performance status of ≤1
* Have histological confirmed sarcoma
* Locally advanced or metastatic sarcoma who receive first-line chemotherapy.
* Have at least one target lesion according to the RECIST criteria.

Exclusion Criteria:

* Pregnant or lactating women
* patient has received chemotherapy drugs including gemcitabine,vincristine and cisplatin
* Chemotherapy within four weeks preceding treatment start
* ECOG ≥ 2
* Radiotherapy to the axial skeleton within the 4 weeks preceding study treatment start or insufficient recovery from the effects of prior radiotherapy
* Participation in any investigational drug study within 4 weeks preceding treatment start
* History of another malignancy within the last five years except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix .Abnormal laboratory values: hemoglobin \< 8. 0g/dl, neutrophil\< 1.5×109/L, platelet\< 100×109/L.
* serum creatine \> upper limit of normal (ULN)
* serum bilirubin \> ULN
* alanine aminotransferase(ALT) and aspartate aminotransferase(AST)\>5×ULN
* alkaline phosphatase(AKP)\>5×ULN
* Serious uncontrolled intercurrence infection
* Life expectancy of less than 3 months